Passive income is the cash flow that arrives whether you are working, sleeping, or watching the market churn. For investors who have spent decades building a paycheck, the appeal of a portfolio that pays you on a fixed schedule is less about getting rich and more about getting reliable. Earned income stops the moment you do. Dividend income does not.
Healthcare and consumer staples have long anchored income portfolios because their cash flows are largely insensitive to recession risk. The trade-off with a blue-chip name is yield: you give up the double-digit headline rate of a mortgage REIT or a BDC in exchange for a check that has not been cut, suspended, or skipped in living memory. For investors who want quarterly reliability over yield maximization, that trade is the entire point.
We screened our 24/7 Wall St. dividend equity research database, looking for stocks that pay durable, growing dividends, and we found a Dividend King that can generate over $115 a year in passive annual income if you invest just $5,000 in it at the time of this writing.
Johnson & Johnson
- Yield: 2.26% (indicated forward yield closer to 2.39% on the new $1.34 quarterly rate)
- Shares for $5,000: 22.3 at $224.20
- Annual Passive Income: $119.54 (about $29.88 every quarter)
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a diversified global healthcare company that operates two reporting segments after the Kenvue spin: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Six priority franchises, oncology, immunology, neuroscience, cardiovascular, surgery, and vision, drove $96.4 billion in trailing-twelve-month revenue and an operating margin of 27.4%.
Q1 2026 revenue rose 9.9% YoY, led by DARZALEX, TREMFYA, CARVYKTI, and a MedTech cardiovascular business absorbing the STELARA biosimilar erosion without breaking stride.
Dividend Aristocrat at a Discount
The dividend yield trails REIT and BDC standards, but the payout is engineered for permanence. JNJ is one of the few U.S. corporations carrying a prime AAA credit rating, and management has now raised the payout for 64 consecutive years.
The most recent hike, announced April 14, lifted the quarterly dividend from $1.30 to $1.34, with a May 26, 2026 ex-dividend date and a June 9, 2026 payment date. Annualized, that is $5.36 per share, up from $4.96 in 2024 and $4.45 in 2022. The cash to fund those raises comes from a balance sheet that produced $19.7 billion in free cash flow last year.
Ownership is overwhelmingly institutional at 76.2% of the float, with Vanguard, BlackRock, and State Street the largest holders, the standard ownership profile of a Dow Jones Industrial Average component. Recent corporate activity has been deliberate: a $1 billion-plus investment in next-generation cell therapy manufacturing in Pennsylvania, the closing of the Intra-Cellular Therapies acquisition that added CAPLYTA, the Halda Therapeutics deal in oral cancer degraders, and a planned separation of the DePuy Synthes orthopaedics business within 18 to 24 months.
Management has also raised FY2026 guidance to $100.3 billion to $101.3 billion in revenue and adjusted EPS of $11.45 to $11.65. CEO Joaquin Duato told investors JNJ “had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact.”
The Bottom Line
A $5,000 stake in JNJ at $224.20 buys roughly 22.3 shares and produces about $119.54 a year in dividends, deposited in four checks of roughly $29.88. That is a 2.39% indicated yield on a stock that has returned 47.59% over the past year and 161.73% over the past decade on a price basis alone.
The argument for a name like JNJ inside a passive income strategy rests on the certainty of the next 64 checks. Reinvested through a DRIP, that $119.54 stream compounds into incrementally larger payouts every quarter as both share count and dividend per share grow. For income investors who measure success in years, not weeks, that quiet accumulation is the entire job.
Top Gaining Stocks
Top Losing Stocks